Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Opus Genetics, Inc. (IRD)
USD3.55
-0.01 (-0.28%)
US NASDAQ Healthcare Biotechnology
Address
37000 Grand River Avenue 48335
Durham, MI, US
Durham, MI, US
CEO
George Magrath
Website
opusgtx.com
IPO
2015-01-19
CIK 1228627 ISIN US67577R1023
Also trades on
NASDAQ Capital Market · OCUP (USD)
NASDAQ Global Market · IRD (USD)
Description
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
News Sentiment (7d)
Based on only 2 articles — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD3.55
-0.01 (-0.28%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
974.1K
Beta
0.55
Float Shares
34.48M
Free Float %
42.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.99% | -9.91% | -21.80% | +13.93% | +102.48% | +103.48% | +300.98% | +217.05% | +217.05% | +217.05% | +217.05% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (7 ratings, all time)
Buy
Price Targets & DCF
Current price
3.55
Low
7.00
+97.2%
Consensus
8.67
+144.2%
Median
9.00
+153.5%
High
10.00
+181.7%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 14 | +1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
10.00
+181.7%
|
| Last Quarter | 2 |
9.50
+167.6%
|
| Last Year | 4 |
8.25
+132.4%
|
| All Time | 4 |
8.25
+132.4%
|
Quality scores
Altman Z-Score
-5.10
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+29.2% ★ Q1'26: -50.6% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+62.8% ★ Q1'26: -212.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-364.1% Q1'26: -590.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-339.0% Q1'26: -665.9% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +71.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+2,229.1% Q1'26: +2,464.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: -0.45× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 13 Rev. Ana. 11 EPS Ana. |
Dec 2027 12 Rev. Ana. 10 EPS Ana. |
Dec 2028 10 Rev. Ana. 9 EPS Ana. |
Dec 2029 5 Rev. Ana. 3 EPS Ana. |
Dec 2030 5 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 1.20M (-100.0%)
|
589.0K
est: 496.3K (+18.7%)
|
39.85M
est: 29.44M (+35.4%)
|
19.05M
est: 22.68M (-16.0%)
|
10.99M
est: 10.10M (+8.8%)
|
14.20M
est: 13.48M (+5.3%)
|
15.50M
9.74M – 25.21M
+15.0% YoY
|
15.51M
1.82M – 30.22M
+0.0% YoY
|
30.88M
30.31M – 31.45M
+99.1% YoY
|
166.19M
47.95M – 295.71M
+438.2% YoY
|
316.02M
91.18M – 562.31M
+90.2% YoY
|
| EBITDA |
-17.77M
est: -255.9K (-6,842.7%)
|
-56.69M
est: -105.8K (-53,462.2%)
|
18.22M
est: -6.28M (+390.2%)
|
-9.97M
est: -4.84M (-106.2%)
|
-57.52M
est: -6.19M (-828.7%)
|
-48.07M
est: -8.27M (-481.5%)
|
-9.51M
-15.46M – -5.97M
-15.0% YoY
|
-9.51M
-18.53M – -1.12M
0.0% YoY
|
-18.94M
-19.29M – -18.59M
-99.1% YoY
|
-101.91M
-181.34M – -29.40M
-438.2% YoY
|
-193.80M
-344.83M – -55.91M
-90.2% YoY
|
| EBIT |
-17.77M
est: -256.0K (-6,843.1%)
|
-56.69M
est: -105.9K (-53,444.7%)
|
18.21M
est: -6.28M (+390.0%)
|
-9.97M
est: -4.84M (-106.2%)
|
-57.53M
est: -6.19M (-828.8%)
|
-48.13M
est: -8.27M (-482.0%)
|
-9.51M
-15.46M – -5.98M
-15.0% YoY
|
-9.51M
-18.53M – -1.12M
0.0% YoY
|
-18.94M
-19.29M – -18.59M
-99.1% YoY
|
-101.93M
-181.36M – -29.41M
-438.2% YoY
|
-193.82M
-344.88M – -55.92M
-90.2% YoY
|
| Net Income |
-24.62M
est: -38.60M (+36.2%)
|
-56.69M
est: -80.28M (+29.4%)
|
17.89M
est: 17.83M (+0.3%)
|
-9.99M
est: -7.95M (-25.6%)
|
-57.53M
est: -58.28M (+1.3%)
|
-49.59M
est: -403.04M (+87.7%)
|
-480.82M
-829.92M – -131.73M
-19.3% YoY
|
-453.22M
-635.69M – -270.76M
+5.7% YoY
|
-265.54M
-437.92M – -93.17M
+41.4% YoY
|
73.89M
5.55M – 148.75M
+127.8% YoY
|
504.00M
37.83M – 1.01B
+582.1% YoY
|
| SGA |
2.82M
est: 4.14M (-32.0%)
|
8.12M
est: 1.71M (+374.1%)
|
7.27M
est: 101.60M (-92.8%)
|
11.96M
est: 78.25M (-84.7%)
|
18.22M
est: 35.96M (-49.4%)
|
21.98M
est: 48.01M (-54.2%)
|
55.19M
34.69M – 89.78M
+15.0% YoY
|
55.22M
6.48M – 107.59M
+0.0% YoY
|
109.95M
107.92M – 111.99M
+99.1% YoY
|
591.75M
170.73M – 1.05B
+438.2% YoY
|
1.13B
324.65M – 2.00B
+90.2% YoY
|
| EPS |
-5.28
est: -1.45 (-265.4%)
|
-3.82
est: -3.01 (-27.1%)
|
0.90
est: 0.67 (+34.8%)
|
-0.46
est: -0.30 (-54.6%)
|
-2.15
est: -1.12 (-92.0%)
|
-0.80
est: -0.67 (-19.9%)
|
-1.06
-1.33 – -0.21
-58.7% YoY
|
-0.74
-1.02 – -0.44
+30.3% YoY
|
-0.44
-0.70 – -0.15
+39.8% YoY
|
0.12
0.01 – 0.24
+126.7% YoY
|
0.81
0.06 – 1.63
+582.1% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-13 | Citizens | Market Outperform | Market Outperform | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-39.00M
OE per share TTM
-0.28
Owner's Yield
-1.10%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
0.6%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
14
Beneficial owners (>5%)
25
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Not Applicable | 9.71M | 7.24% | 8.31M | 1.40M | 8.31M | 1.40M | IN | U.S.A. | 2013-10-09 | ↗ |
| 2 | Teva Pharmaceutical Industries Limited | 5.44M | 6.30% | 5.44M | — | 5.44M | — | CO | Israel | 2011-01-28 | ↗ |
| 3 | Altium Capital Management, LP | 2.68M | 4.99% | — | 2.68M | — | — | PN | United States of America | 2022-02-14 | ↗ |
| 4 | Altium Growth Fund, LP | 2.68M | 4.99% | — | 2.68M | — | — | PN | United States of America | 2022-02-14 | ↗ |
| 5 | Growth GP, LLC | 2.68M | 4.99% | — | 2.68M | — | — | OO | United States of America | 2022-02-14 | ↗ |
| 6 | Foundation Fighting Blindness Retinal Degeneration Fund | 2.56M | 8.16% | — | 2.56M | — | 2.56M | CO, OO | — | 2024-10-29 | ↗ |
| 7 | Foundation Fighting Blindness, Inc. | 2.56M | 8.16% | — | 2.56M | — | 2.56M | CO | — | 2024-10-29 | ↗ |
| 8 | 13G | 1.92M | 5.10% | — | 1.92M | — | 1.92M | HC, OO | Canadian Citizen | 2018-10-29 | ↗ |
| 9 | CVI Investments, Inc. | 1.92M | 5.10% | — | 1.92M | — | 1.92M | CO | Cayman Islands | 2018-10-26 | ↗ |
| 10 | Heights Capital Management, Inc. | 1.92M | 5.10% | — | 1.92M | — | 1.92M | CO | Delaware | 2018-10-26 | ↗ |
| 11 | Mina Sooch | 1.29M | 6.70% | 1.29M | — | 1.29M | — | IN | United States America | 2022-02-14 | ↗ |
| 12 | Matthew J. Curfman | 1.19M | 6.20% | 18.0K | 33.4K | 18.0K | 1.14M | IN | Citizenship or Place of Organization | 2022-05-17 | ↗ |
| 13 | David S. Richmond | 1.18M | 6.12% | 722.00 | 33.4K | 722.00 | 1.14M | IN | Citizenship or Place of Organization | 2022-05-17 | ↗ |
| 14 | Richmond Brothers, Inc. | 1.12M | 5.84% | — | — | 98.7K | 1.02M | IA, CO | Citizenship or Place of Organization | 2022-05-17 | ↗ |
| 15 | Apexian Pharmaceuticals, Inc. | 780.0K | 7.14% | 780.0K | — | 780.0K | — | CO | Delaware | 2021-03-26 | ↗ |
| 16 | Empery Asset Management, LP | 591.0K | 8.33% | — | 591.0K | — | — | PN | Delaware | 2020-11-12 | ↗ |
| 17 | Martin D. Hoe | 591.0K | 8.33% | — | 591.0K | — | — | IN | United States | 2020-11-12 | ↗ |
| 18 | Ryan M. Lane | 591.0K | 8.33% | — | 591.0K | — | — | IN | United States | 2020-11-12 | ↗ |
| 19 | Empery Debt Opportunity Fund, LP | 537.8K | 7.58% | — | 537.8K | — | — | PN | Delaware | 2020-11-12 | ↗ |
| 20 | RBI PI MANAGER, LLC | 364.9K | 5.10% | — | — | 364.9K | — | OO | DELAWARE | 2020-11-16 | ↗ |
| 21 | Altium Growth GP, LLC | 314.8K | 9.99% | — | 314.8K | — | — | OO | Delaware, United States of America | 2021-02-16 | ↗ |
| 22 | The RBI Opportunities Fund II, LLC | 275.0K | 1.43% | 275.0K | — | 275.0K | — | OO | Citizenship or Place of Organization | 2022-05-17 | ↗ |
| 23 | RBI Private Investment III, LLC | 247.6K | 1.29% | 247.6K | — | 247.6K | — | OO | Citizenship or Place of Organization | 2022-05-17 | ↗ |
| 24 | THE RBI OPPORTUNITIES FUND, LLC | 231.5K | 3.30% | — | — | 231.5K | — | OO | DELAWARE | 2020-11-16 | ↗ |
| 25 | Richmond Brothers 401(k) Profit Sharing Plan | 33.4K | 1.00% | 33.4K | — | 33.4K | — | EP | Citizenship or Place of Organization | 2022-05-17 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 37 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.45% | 98.6K | 0.20% |
| 2 | iShares Micro-Cap ETF IWC | 0.05% | 704.7K | 0.60% |
| 3 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.03% | 336.9K | 0.20% |
| 4 | iShares Russell 2000 Growth ETF IWO | 0.01% | 1.98M | 0.24% |
| 5 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.01% | 197.4K | 0.30% |
| 6 | EA Bridgeway Omni Small-Cap Value ETF BSVO | 0.01% | 114.8K | 0.47% |
| 7 | Global X - Russell 2000 ETF RSSL | 0.01% | 98.2K | 0.08% |
| 8 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.01% | 21.2K | 0.25% |
| 9 | iShares Russell 2000 BuyWrite ETF IWMW | 0.01% | 3.7K | 0.39% |
| 10 | iShares Russell 2000 ETF IWM | 0.01% | 5.39M | 0.19% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.00
Neutral
Ratio by volume
0.10
Bearish
Buys
7
Sells
7
Shares acquired
170.6K
Shares disposed
1.74M
Cash buys
—
Cash sales
7.00
Net activity
-1,568,134
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | Foundation Fighting Blindness Retinal Degeneration Fund | Director | S-Sale | D | Common Stock | 1,700,000 | 4.35 | 7.40M | 3,792,171 | D | ↗ |
| 2026-04-23 | Zaremba Rabourn Amy | Officer | S-Sale | D | Common Stock | 1,641 | 5.20 | 8.5K | 188,671 | D | ↗ |
| 2026-04-23 | YERXA BENJAMIN R | Director / Officer | S-Sale | D | Common Stock | 7,470 | 5.24 | 39.1K | 711,535 | D | ↗ |
| 2026-04-23 | SCHACHLE JOSEPH K | Officer | S-Sale | D | Common Stock | 4,697 | 5.22 | 24.5K | 296,084 | D | ↗ |
| 2026-04-23 | Magrath George | Director / Officer | S-Sale | D | Common Stock | 9,511 | 5.22 | 49.6K | 1,741,344 | D | ↗ |
| 2026-04-23 | Jayagopal Ashwath | Officer | S-Sale | D | Common Stock | 7,542 | 5.19 | 39.2K | 509,233 | D | ↗ |
| 2026-04-23 | Gagnon Robert E. | Officer | S-Sale | D | Common Stock | 7,842 | 5.18 | 40.7K | 592,158 | D | ↗ |
| 2026-04-20 | Rodgers Richard J | Director | A-Award | A | Common Stock | 24,367 | 0.00 | — | 343,022 | D | ↗ |
| 2026-04-20 | MANUSO JAMES S J | Director | A-Award | A | Common Stock | 24,367 | 0.00 | — | 317,318 | D | ↗ |
| 2026-04-20 | Graves Adrienne L | Director | A-Award | A | Common Stock | 24,367 | 0.00 | — | 127,514 | D | ↗ |
| 2026-04-20 | Gallagher Cam | Director | A-Award | A | Common Stock | 24,367 | 0.00 | — | 2,015,797 | D | ↗ |
| 2026-04-20 | Benton Susan | Director | A-Award | A | Common Stock | 24,367 | 0.00 | — | 243,894 | D | ↗ |
| 2026-04-20 | Bennett Jean | Director | A-Award | A | Common Stock | 24,367 | 0.00 | — | 259,019 | D | ↗ |
| 2026-04-20 | Ainsworth Sean | Director | A-Award | A | Common Stock | 24,367 | 0.00 | — | 321,692 | D | ↗ |
| 2026-03-16 | Zaremba Rabourn Amy | Officer | S-Sale | D | Common Stock | 2,816 | 5.25 | 14.8K | 190,312 | D | ↗ |
| 2026-03-16 | SCHACHLE JOSEPH K | Officer | S-Sale | D | Common Stock | 3,719 | 5.25 | 19.5K | 300,781 | D | ↗ |
| 2026-03-16 | Magrath George | Director / Officer | S-Sale | D | Common Stock | 24,438 | 5.21 | 127.3K | 1,750,855 | D | ↗ |
| 2026-03-16 | Jayagopal Ashwath | Officer | S-Sale | D | Common Stock | 3,719 | 5.12 | 19.0K | 516,775 | D | ↗ |
| 2026-02-12 | Jayagopal Ashwath | Officer | F-InKind | D | Common Stock | 5,313 | 3.39 | 18.0K | 520,494 | D | ↗ |
| 2026-01-22 | Zaremba Rabourn Amy | Officer | A-Award | A | Common Stock | 86,500 | 0.00 | — | 193,128 | D | ↗ |
| 2026-01-22 | YERXA BENJAMIN R | Director / Officer | A-Award | A | Common Stock | 400,000 | 0.00 | — | 719,005 | D | ↗ |
| 2026-01-22 | SCHACHLE JOSEPH K | Officer | A-Award | A | Common Stock | 250,000 | 0.00 | — | 304,500 | D | ↗ |
| 2026-01-22 | Magrath George | Director / Officer | A-Award | A | Common Stock | 483,639 | 0.00 | — | 1,775,293 | D | ↗ |
| 2026-01-22 | Jayagopal Ashwath | Officer | A-Award | A | Common Stock | 400,000 | 0.00 | — | 525,807 | D | ↗ |
| 2026-01-22 | Gagnon Robert E. | Officer | A-Award | A | Common Stock | 400,000 | 0.00 | — | 600,000 | D | ↗ |
| 2026-01-18 | Zaremba Rabourn Amy | Officer | F-InKind | D | Common Stock | 3,390 | 2.10 | 7.1K | 106,628 | D | ↗ |
| 2026-01-10 | Zaremba Rabourn Amy | Officer | F-InKind | D | Common Stock | 3,950 | 1.93 | 7.6K | 110,018 | D | ↗ |
| 2026-01-06 | Gallagher Cam | Director | A-Award | A | Common Stock | 67,000 | 0.00 | — | 1,991,430 | D | ↗ |
| 2026-01-01 | MANUSO JAMES S J | Director | A-Award | A | Common Stock | 31,188 | 1.99 | 62.1K | 292,951 | D | ↗ |
| 2026-01-01 | Graves Adrienne L | Director | A-Award | A | Common Stock | 23,643 | 1.99 | 47.0K | 103,147 | D | ↗ |
| 2026-01-01 | Bennett Jean | Director | A-Award | A | Common Stock | 21,127 | 1.99 | 42.0K | 234,652 | D | ↗ |
| 2026-01-01 | Ainsworth Sean | Director | A-Award | A | Common Stock | 42,507 | 1.99 | 84.6K | 297,325 | D | ↗ |
| 2025-12-31 | Gallagher Cam | Director | A-Award | A | Common Stock | 33,000 | 0.00 | — | 1,924,430 | D | ↗ |
| 2025-12-29 | Gallagher Cam | Director | P-Purchase | A | Common Stock | 83,000 | 1.97 | 163.4K | 83,000 | I | ↗ |
| 2025-12-09 | Foundation Fighting Blindness Retinal Degeneration Fund | Director | S-Sale | D | Common Stock | 4,000,000 | 2.15 | 8.60M | 5,492,171 | D | ↗ |
| 2025-11-01 | Magrath George | Director / Officer | F-InKind | D | Common Stock | 30,350 | 2.30 | 69.8K | 1,291,654 | D | ↗ |
| 2025-10-22 | YERXA BENJAMIN R | Director / Officer | F-InKind | D | Common Stock | 23,795 | 1.95 | 46.4K | 319,005 | D | ↗ |
| 2025-09-10 | Gagnon Robert E. | Officer | A-Award | A | Common Stock | 200,000 | 0.00 | — | 200,000 | D | ↗ |
| 2025-09-02 | Gagnon Robert E. | Officer | A-Award | A | Employee Stock Option (right to buy) | 250,000 | 1.23 | 307.5K | 250,000 | D | ↗ |
| 2025-08-25 | Gallagher Cam | Director | A-Award | A | Common Stock | 869,565 | 1.15 | 1,000.0K | 1,810,430 | D | ↗ |
| 2025-08-25 | Ainsworth Sean | Director | A-Award | A | Common Stock | 86,956 | 1.15 | 100.0K | 254,818 | D | ↗ |
| 2025-05-05 | Foundation Fighting Blindness Retinal Degeneration Fund | Director / 10% Owner | C-Conversion | D | Series A Non-Voting Convertible Preferred Stock | 6,927 | 0.00 | — | 0 | D | ↗ |
| 2025-04-30 | Rodgers Richard J | Director | A-Award | A | Stock Option (Right to Buy) | 79,592 | 0.95 | 75.6K | 79,592 | D | ↗ |
| 2025-04-30 | MANUSO JAMES S J | Director | A-Award | A | Common Stock | 79,504 | 0.00 | — | 261,763 | D | ↗ |
| 2025-04-30 | Graves Adrienne L | Director | A-Award | A | Common Stock | 79,504 | 0.00 | — | 79,504 | D | ↗ |
| 2025-04-30 | Gallagher Cam | Director | A-Award | A | Stock Option (Right to Buy) | 79,592 | 0.95 | 75.6K | 79,592 | D | ↗ |
| 2025-04-30 | Benton Susan | Director | A-Award | A | Common Stock | 79,504 | 0.00 | — | 219,527 | D | ↗ |
| 2025-04-30 | Bennett Jean | Director | A-Award | A | Stock Option (Right to Buy) | 79,592 | 0.95 | 75.6K | 79,592 | D | ↗ |
| 2025-04-30 | Ainsworth Sean | Director | A-Award | A | Common Stock | 79,504 | 0.00 | — | 167,862 | D | ↗ |
| 2025-03-24 | Magrath George | Director / Officer | A-Award | A | Common Stock | 392,157 | 0.00 | — | 1,322,004 | D | ↗ |
| 2025-03-24 | Gallagher Cam | Director | A-Award | A | Common Stock | 784,314 | 0.00 | — | 861,361 | D | ↗ |
| 2025-03-13 | Zaremba Rabourn Amy | Officer | A-Award | A | Employee Stock Option (right to buy) | 39,500 | 0.93 | 36.7K | 39,500 | D | ↗ |
| 2025-03-13 | SCHACHLE JOSEPH K | Officer | A-Award | A | Employee Stock Option (right to buy) | 52,500 | 0.93 | 48.8K | 52,500 | D | ↗ |
| 2025-03-13 | Magrath George | Officer | A-Award | A | Employee Stock Option (right to buy) | 330,697 | 0.93 | 307.5K | 330,697 | D | ↗ |
| 2025-03-13 | Jhaveri Nirav S. | Officer | A-Award | A | Common Stock | 52,500 | 0.00 | — | 194,293 | D | ↗ |
| 2025-03-13 | Jayagopal Ashwath | Officer | A-Award | A | Employee Stock Option (right to buy) | 52,500 | 0.93 | 48.8K | 52,500 | D | ↗ |
| 2025-03-13 | Hoffmann Bernhard | Officer | A-Award | A | Common Stock | 29,500 | 0.00 | — | 185,446 | D | ↗ |
| 2025-02-13 | Jhaveri Nirav S. | Officer | F-InKind | D | Common Stock | 8,207 | 1.15 | 9.4K | 141,793 | D | ↗ |
| 2025-02-13 | Jayagopal Ashwath | Officer | F-InKind | D | Common Stock | 5,193 | 1.15 | 6.0K | 73,307 | D | ↗ |
| 2025-02-04 | Zaremba Rabourn Amy | Officer | F-InKind | D | Common Stock | 8,190 | 1.14 | 9.3K | 74,468 | D | ↗ |
| 2025-02-04 | Hoffmann Bernhard | Officer | F-InKind | D | Common Stock | 6,751 | 1.14 | 7.7K | 155,946 | D | ↗ |
| 2025-01-02 | MANUSO JAMES S J | Director | A-Award | A | Common Stock | 50,222 | 1.23 | 61.8K | 182,259 | D | ↗ |
| 2025-01-02 | Bennett Jean | Director | A-Award | A | Common Stock | 34,021 | 1.23 | 41.8K | 134,021 | D | ↗ |
| 2024-12-26 | Magrath George | Officer | P-Purchase | A | Common Stock | 100,000 | 0.98 | 97.6K | 599,150 | D | ↗ |
| 2024-12-23 | Magrath George | Officer | A-Award | A | Common Stock | 6,200 | 0.00 | — | 499,150 | D | ↗ |
| 2024-11-21 | YERXA BENJAMIN R | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 0.98 | 9.8K | 342,800 | D | ↗ |
| 2024-11-18 | Magrath George | Officer | P-Purchase | A | Common Stock | 9,706 | 1.02 | 9.9K | 492,950 | D | ↗ |
| 2024-11-15 | Magrath George | Officer | P-Purchase | A | Common Stock | 90,294 | 1.01 | 91.2K | 483,244 | D | ↗ |
| 2024-11-07 | YERXA BENJAMIN R | Director / Officer | A-Award | A | Common Stock | 332,800 | 0.00 | — | 332,800 | D | ↗ |
| 2024-11-01 | Magrath George | Officer | F-InKind | D | Common Stock | 37,050 | 1.18 | 43.7K | 392,950 | D | ↗ |
| 2024-10-22 | YERXA BENJAMIN R | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-10-22 | Graves Adrienne L | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-10-22 | Foundation Fighting Blindness Retinal Degeneration Fund | Director | — | — | Series A Non-Voting Convertible Preferred Stock | 6,927 | 0.00 | — | 0 | D | ↗ |
| 2024-10-22 | Bennett Jean | Director | A-Award | A | Stock Option (right to buy) | 172,874 | 1.33 | 229.9K | 172,874 | D | ↗ |
Executive team
Top executives
EBIT / Employee
-26.7K
Shares Outstanding
81.40M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Dr. George Magrath Chief Executive Officer | 598.0K | — | 307.5K | 212.0K | 361.8K | 14.0K | 1.49M | 34.79% | ↗ |
| 2 | 2025 | Dr. Ashwath Jayagopal Chief Scientific and Development Officer | 416.0K | 50.0K | 48.8K | 33.7K | 205.9K | 10.4K | 764.8K | 10.78% | ↗ |
| 3 | 2025 | Joseph Schachle Chief Operating Officer | 416.0K | — | 48.8K | 33.7K | 205.9K | 14.0K | 718.4K | 11.48% | ↗ |
| 4 | 2024 | Dr. Ashwath Jayagopal Chief Scientific and Development Officer | 354.0K | 50.0K | 199.5K | 477.3K | 151.3K | 10.0K | 1.24M | 54.48% | ↗ |
| 5 | 2024 | Dr. George Magrath Chief Executive Officer | 575.0K | — | — | — | 300.4K | 13.8K | 889.2K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| George Magrath | Chief Executive Officer & Director | 973.8K | male |
| Ashwath Jayagopal | Chief Scientific & Development Officer | 682.4K | — |
| Joseph K. Schachle | Chief Operating Officer | 635.9K | male |
| Bernhard Hoffmann | Senior Vice President of Corporate Development & Secretary | 434.1K | male |
| Amy Zaremba Rabourn | Head of Financial Quality Assurance | 434.1K | female |
| Robert E. Gagnon | Chief Financial Officer & Principal Accounting Officer | — | male |
| Sally Tucker | Chief Medical Officer & Senior Vice President of Clinical Development | — | female |
| Benjamin R. Yerxa | President & Director | — | — |
| Bindu Manne | Head of Market Development & Commercialization | — | female |
| Chris Ernst | Chief Technology Officer | — | male |
| Jenny Kobin | Investor Relations Officer | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IRD
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
